2021 has been a great year for our PMS product - we had a return of 54% till date as against 29% for the NSE 500!
As of November end, on a relative basis, we are far ahead of all large or multicap PMS schemes. Even more important, these returns came with extremely low volatility such that on risk-adjusted measure (Returns/ Volatility or Gain to Pain ratio), we are at roughly double the rate of all others.
This performance comes out of not any single human being's brain waves but through a consistent, replicable Human plus Machine system which is what we use for all our products. We have a blended investment strategy which is designed taking into consideration multiple factors like Value, Growth, Price Movement, Valuation, Quality of Stock, Overall Market Dynamics, etc. Essentially, it is a bias-free approach to investing. Our Model is purely clinical. It doesn't storify investing.
Our strategy is one of taking a large number of small bets as opposed to the conventional strategy of taking a small number of large bets. As a result of this diversification, we have found that one can generate tons of alpha (extra return) without adding proportionately to risk.
Avoidance of big losses is absolutely central to our investment process and Risk Management is the God we worship. This includes not just strict stop losses but also other factors like being extremely careful on market cap and liquidity norms (for example we never have a very high weightage to small caps even when they look attractive), looking at how different sectors and asset classes move together to prevent any outsized risk to any one sector or factor.
Our philosophy is to first manage the risk even before we look at the returns and the results are there for all to see.
We have an extensive techstack called FG Exotech with a series of subsystems that help us identify every attractive opportunity in the Indian market, as well as globally. The last two years have been years where more nimbleness than usual has been required and we have managed to catch most big trends.
For example we bet on the re-rating of the IT sector in India about a year and a half ago which has played out beautifully. This is a sector that we continue to like. We have also invested in commodities, specially metals and power but lightened up on these a few months ago. Capital goods has also being a good performer for us.
In 2022, many macro factors will remain important including a possible depreciation of the Rupee which makes exports/ import substitution sectors more attractive. Interest rate changes will need to be watched carefully both in India and globally.
Our philosophy is be neither Bullish nor Bearish but to remain Hare-ish. To be alert like a Hare will 360 degree vision, to move fast but to be able to change direction as well.
(A version of this article first appeared in AifPMS publication)
From the desk of Devina Mehra
Or WhatsApp us on +91 88501 69753
Economists Think Dollar's Fall May Explain the Recent ‘Rally’ by Steve Liesman
Einstein taught us about relativity in nature. Now come Devina Mehra and Shankar Sharma of First Global to teach us about relativity in financial markets -- and raise some serious questions about just what is driving stock prices.
First Global reports are quite credible and, on occasion, more than that.
What prompts this mention is Intel's earnings report and the fact that First Global has had a pretty good bead on the company and its stock.
AMD up again following First Global upgrade to ‘buy’ (AMD) By Tomi Kilgore
Analyst Kuldeep Koul at First Global upgraded Advanced Micro Devices (AMD) to "buy" from "outperform," given the "exceptional traction" that the chipmaker's Opteron line of processors has been able to get.
Baidu Climbs on First Global’s ‘Outperform’ Outlook
Baidu Inc., the operator of China’s most-used Internet search engine, rose to the highest price in two weeks after First Global rated the shares “outperform? in new coverage.
Personality counts: Walmart's frugal, but Target charms
"It's better to take a slight hit on [profit] margins and keep on moving and inventing," says First Global Securities. And at least for now, Target is inventing in a way that appeals to consumers with money to spend.
At 11 times trailing earnings, Energizer is cheaper; Gillette's multiple is 25. But cheaper doesn't mean better, says First Global.
Bipinchandra Dugam @bipinchandra90
invested in both GFF-GTS and Super I50. Thank you very much for such wonderful investing experience with completely new approach. In my 15years of investing first product I felt which close to what customer want.
Shishir Kapadia @shishirkapadia1
by far you are the best, I have not come across transparency, acumen, global expertise, exposure, protection of capital, delivering return from any fund/ fund managers. Invested very small size in 3 products will keep on increasing it over the period